a n a ly s i s Elucidating the molecular drivers of human breast cancers requires a strategy that is capable of integrating multiple forms of data and an ability to interpret the functional consequences of a given genetic aberration. Here we present an integrated genomic strategy based on the use of gene expression signatures of oncogenic pathway activity (n = 52) as a framework to analyze DNA copy number alterations in combination with data from a genome-wide RNA-mediated interference screen. We identify specific DNA amplifications and essential genes within these amplicons representing key genetic drivers, including known and new regulators of oncogenesis. The genes identified include eight that are essential for cell proliferation (FGD5, METTL6, CPT1A, DTX3, MRPS23, EIF2S2, EIF6 and SLC2A10) and are uniquely amplified in patients with highly proliferative luminal breast tumors, a clinical subset of patients for which few therapeutic options are effective. This general strategy has the potential to identify therapeutic targets within amplicons through an integrated use of genomic data sets.
Tumorigenesis is driven by a combination of inherited and acquired genetic alterations resulting in a complex and heterogeneous disease. The ability to dissect this heterogeneity is critical to understanding the relevance of these alterations for disease phenotypes but also to enable the development of rational therapeutic strategies that can match the characteristics of the individual patient's tumor. Many studies, including reports from The Cancer Genome Atlas (TCGA) project, have made use of the power of multiplatform genomic analyses to identify known and new genetic drivers of tumor phenotypes [1] [2] [3] . This has led to the identification of disease subgroups with distinct characteristics and, in some instances, distinct genetic mechanisms of disease 1, 2, 4 . The strength of this approach relies on the integration of large-scale genomic data to reveal biological covariation that cannot be identified when using a single technology. A weakness of this approach is in the interpretation of the underlying biology, which generally represents an inference about pathway activity based on prior knowledge concerning an individual gene mutation or protein alteration.
Altered signaling pathway activity is an important determinant of the biology of a tumor and may predict therapeutic response; therefore, identifying the mechanisms driving key tumorigenic pathways is essential to understanding the transformation process 2, [5] [6] [7] [8] . To take advantage of the vast amounts of existing genomic data, we used a series of experimentally derived gene expression signatures that are capable of measuring oncogene or tumor suppressor pathway activity, aspects of the tumor microenvironment and other tumor characteristics, including proliferation rate, as a framework by which to integrate multiple forms of genomic data. Our results identify patterns of oncogenic signaling within each of the molecular subtypes of breast cancer, many of which correlate directly with DNA copy number aberrations. By further analyzing functional data from a genome-wide RNA-mediated interference (RNAi) screen 9 , we identified genes that are essential for cell viability in a pathway-dependent and, in some cases, subtype-dependent manner. Our results identify a small number of DNA amplifications as potential drivers of proliferation in poor-outcome luminal breast cancers, and in general terms, we outline an approach that could be applied to many other tumor types for which multiplatform genomic data exist.
RESULTS

Subtype-specific patterns of oncogenic signaling
To objectively identify genetic drivers of breast cancer, we examined genomic-based patterns of oncogenic pathway activity, the tumor microenvironment and other important features in human breast tumors using a panel of 52 previously published gene expression signatures ( Supplementary Tables 1 and 2 ) . We applied each signature to the breast cancer gene expression microarray data (n = 476) from the TCGA project (Supplementary Table 3 ), for which the molecular intrinsic subtype had been determined 2 . Consistent patterns of pathway activity emerged for each subtype (as illustrated in Fig. 1a) , and we quantitatively assessed these patterns using an analysis of variance (ANOVA) test followed by Tukey's test for pairwise comparison (Fig. 1b and Supplementary Table 4 ). Analyzing differences across subtypes on the basis of these 52 features demonstrated that the strongest correlation between samples existed within each molecular subtype (Supplementary Fig. 1) .
The patterns of pathway activity recapitulated known characteristics of each subtype, including dysregulation of pathways that can be linked to female hormone receptors, oncogenes and/or tumor suppressor mutation status (Fig. 1) . For example, basal-like tumors, a n a ly s i s which represent ~80% of triple-negative breast cancers, are characterized by low hormone receptor signaling, mutant p53 signaling and high expression of proliferation pathway activity (Fig. 1) . Likewise, HER2-enriched (HER2E) tumors show high expression of the HER2 (ref. 11) and HER2 amplicon (HER2-AMP) 12 signatures, whereas luminal A (LumA) tumors show high hormone receptor signaling and wild-type p53 signaling. Highly proliferative LumB tumors, which also show some hormone receptor signaling, are distinguished from less proliferative LumA samples by increased proliferation-associated pathways. Thus, these data robustly recapitulate many previously published pathway and subtype associations.
Calculating a Pearson correlation coefficient to assess the concordance between each of the 52 signatures ( Supplementary Fig. 2 and Supplementary Table 5) identified strong relationships between independent signatures for a given pathway, as well as between related pathways. For example, two MYC signatures 11, 15, 32 demonstrated an R value of 0.72, whereas PIK3CA 18 and PTEN-deleted 27 signatures had an R value of 0.82. Signatures scoring different pathways were also concordant; for instance, MYC-mediated regulation of E2F signaling 33 was identified by the association between the RB loss of heterozygosity (RB-LOH) 16 and MYC 15 signatures (R = 0.79), whereas EGFR-mediated activation of STAT33 signaling 34 was recapitulated by the EGFR 11, 32 and STAT3 (refs. 11,32) (R = 0.72) signatures. These results provide a measure of validity for each signature, but because differences do exist between signatures for a specific pathway, the results suggest that each signature provides an opportunity to investigate a particular pathway, taking into account the genetic manipulation used to develop a given signature.
Characterization of pathway-specific copy number alterations
We next used DNA copy number data from the TCGA project (n = 476) to identify copy number alterations (CNAs) associated with pathway activity (Fig. 2a) . We first identified genes for which CNAs were positively (or inversely) correlated with pathway activity using a Spearman rank correlation (Bonferroni corrected to control the familywise error rate) to assess the relationship between pathway P < 0.001 P < 0.01 BRCA1  HER1 C2  P53 MUT  E2 REPRESSED (IIE)  PROLIFERATION (PAM50)  ESC HUMAN  βCATENIN  BMYB  PROLIFERATION  PTEN_DEL  RBLOH  HER1 C3  MYC DUKE  ACTIVE ENDOTHELIUM  MYC UNC  PIK3CA  RAS  HER1 C1  GYCOLYSIS  VEGF/HYPOXIA  E2F1  PI3K  STEM CELL  P63  IFNA  IFNG  STAT1  TNFA  GLUCOSE DEPLETION  CMYB  HYPOXIA  AKT  FOS JUN  ACIDOSIS  STROMAL UP  WOUND RESPONSE  LKB1  HER2  EGFR  STAT3  TGFB  GATA3  HER2 AMP  LACTIC ACID  STROMAL DOWN  ER  PR  P53  E2 ACTIVATED (IE)  P53 WT  PTEN WT  SRC   BRCA1  HER1 C2  P53 MUT  E2 REPRESSED (IIE)  PROLIFERATION (PAM50)  ESC HUMAN  βCATENIN  BMYB  PROLIFERATION  PTEN_DEL  RBLOH  HER1 C3  MYC DUKE  ACTIVE ENDOTHELIUM  MYC UNC  PIK3CA  RAS  HER1 C1  GYCOLYSIS  VEGF/HYPOXIA  E2F1  PI3K  STEM CELL  P63  IFNA  IFNG  STAT1  TNFA  GLUCOSE DEPLETION  CMYB  HYPOXIA  AKT  FOS JUN  ACIDOSIS  STROMAL UP  WOUND RESPONSE  LKB1  HER2  EGFR  STAT3  TGFB  GATA3  HER2 AMP  LACTIC ACID  STROMAL DOWN  ER  PR  P53  E2 npg a n a ly s i s score and gene-level DNA segment score ( Supplementary Fig. 3 Fig. 4 and Supplementary Tables 6-57). To reduce potential false-positive results associated with either strategy alone, for each signature we focused on those genes that were significant in both analyses (Fig. 2a) ; potential drivers of pathway activity had a positive correlation and a higher amplification frequency in samples with high pathway activity, whereas potential repressors had a negative correlation and increased frequency of copy number losses.
Mapping genes that met these criteria to chromosomal loci identified pathway-specific patterns of CNAs (Fig. 2b) . Consistent with previous studies reporting that basal-like tumors have a higher incidence and larger spectrum of CNAs 2, 35 , pathways associated with basallike tumors had more complex patterns of CNAs when compared to luminal-associated pathways.
To further assess the validity of this strategy, we investigated the relationship between pathway activity and a chromosomal alteration of known causative activity. We first focused on the HER2-AMP signature 12 , as this signature is comprised of genes located at the 17q loci and the ERBB2/17q amplification is the dominant driver of this pathway. ERBB2 was amplified in 84.9% of samples with high (top quartile) pathway activity compared to in 7.3% of low-scoring samples (q = 1.1 × 10 −55 ); likewise, this relationship had a positive Spearman rank correlation (q = 2.4 × 10 −108 ) ( Fig. 2c and Supplementary  Table 27 ). Although several other alterations, including MYC amplification (q = 1.1 × 10 −2 and q = 6.3 × 10 −3 ), were also associated with this signature, thus identifying a previously known relationship 36 , ERBB2/17q amplification was the dominant alteration identified, providing a robust positive control for this strategy. As expected, we observed similar results when analyzing the HER2 pathway using the independently developed HER2 (refs. 11,32) signature (Supplementary Table 26) .
We further validated this strategy by assessing the relationship between CNAs and pathways that are associated with a more complex genomic landscape. Previous studies from our group have suggested that the HER1-C2 (ref. 13 ) signature measures predominantly the RAS-RAF-MEK arm of the EGFR pathway 13 . Consistent with this observation, we detected a correlation between the HER1-C2 signature (q < 0.01) and GRB2, SOS1, KRAS, BRAF, PIK3CA, PIK3CB and MYC genomic DNA amplifications, as well as a negative correlation (q < 0.01) with loss of NF1 and the PI3K repressors INPP4B and PTEN ( Fig. 2d and npg a n a ly s i s RB-E2F components, including loss of RB1 and gains of E2F1 and/or E2F3. Consistent with the role of the RB-E2F pathway in mediating cell cycle progression and proliferation 37 , CCND2, CCND3 and MYC amplification also correlated with this signature. Collectively these results demonstrate that this strategy is able to link CNAs with pathway activity and does so by focusing on all aspects of the pathway, often beyond the dominant regulator, potentially allowing for the identification of new regulatory components.
Identification of amplified genes linked to pathway activity
Given the ability of this strategy to identify known CNAs of pathway activity, we next used this approach to identify new drivers of pathway activity. Because highly proliferative luminal tumors have a poor prognosis and poor responses to existing therapies 38, 39 , we sought to identify amplified genes and/or CNAs associated with our previously published 11-gene PAM50 proliferation signature with the hope that these might represent targetable drivers of oncogenesis.
To identify those genes that are altered specifically in highly proliferative luminal tumors while excluding those that are associated with proliferation irrespective of subtype, we performed analyses on two subsets of samples: all tumors and all non-basal like tumors (henceforth called luminal tumors). Some rationale for this binary distinction comes from recent TCGA studies in which 12 tumor types were studied simultaneously, and the results showed that breast tumors formed two groups, namely basal-like and all other breast tumors (called luminal and including HER2 + tumors), suggesting that breast cancer might be considered broadly as two main disease types 40 .
Examining the TCGA breast cancer data set using the PAM50 proliferation signature 31 , we found that basal-like, LumB and HER2E tumors had the highest proliferation levels (Fig. 3a,b) , with the top quartile (Fig. 3c ) comprised of patients with basal-like (49.6%), LumB (33.6%) and HER2E (16.8%) tumors, whereas the top quartile of proliferative luminal tumors (Fig. 3d) contained patients with LumB (68.0%) and HER2E (32.0%) tumors. Using the PAM50 proliferation signature, we examined the frequency of CNA gains and losses in highly proliferative (top quartile) tumors relative to less proliferative samples irrespective of subtype using the statistical strategies discussed previously (Fig. 3e,f and Supplementary Table 43 ). To identify genes that are specifically amplified in highly proliferative luminal breast cancer, we repeated these analyses using the luminal tumor subset (Figs. 3g,h and Supplementary Table 58) . Analyzing both populations of tumors identified three classes of proliferation-associated regions (q < 0.05): (i) CNAs associated irrespective of subtype, (ii) CNAs altered in basal-like tumors, and (iii) CNAs altered in highly proliferative luminal tumors. These results allowed us to focus our analyses on those genes within regions that are uniquely altered in highly proliferative luminal tumors by censoring proliferation-associated genes that are altered in basal-like breast cancer (e.g., TP53 or INPP4B loss) or that are altered irrespective of molecular subtype (e.g., RB1 loss or MYC amplification). These analyses identified a number of 
Identification of pathway-specific essential genes
To distinguish essential from nonessential genes in amplified regions that are associated with proliferation in luminal tumors, we next examined data from a genome-wide RNAi screen of multiple breast tumorderived cell lines 9 . We applied the 52 gene expression signatures to a panel (GSE12777) 41 of breast cancer cell lines ( Supplementary  Fig. 5 and Supplementary Table 59 ), 27 of which had mRNA expression data and were also part of an RNAi proliferation screen in which a genome-wide shRNA library (~16,000 genes) had been used to identify essential genes (Fig. 4a) 9 . For each signature, we used a negative Spearman rank correlation to identify pathway-specific essential genes ( Fig. 4b and Supplementary Table 60 ) by comparing the pathway score against the normalized shRNA score across the panel of 27 cell lines. These analyses identified inverse relationships between the abundance of shRNAs targeting key regulatory genes and pathway scores. For instance, examining the ER 11, 32 , HER2 (refs. 11, 32) (Fig. 4c-e) showed a negative correlation between pathway score and shRNA against ESR1 (P = 0.0143), ERBB2 (P = 0.0227) and STAT1 (P = 0.0049) or JAK3 (P = 0.00013), respectively. These associations were expected for the ER and HER2 pathways given the relationship between HER2 or ER-α mRNA and/or protein expression and the response of cell lines or tumors to trastuzumab or anti-estrogen therapies, respectively. These results confirm that this approach is able to identify essential genes that are known to be functionally associated with pathway activity, thereby suggesting that these data can serve as a biological filter to distinguish pathway-specific essential from nonessential genes.
Amplified essential genes linked to luminal tumor proliferation
We next sought to distinguish between essential and nonessential genes within regions amplified specifically in highly proliferative luminal tumors. For each subset of tumors, we identified genes in amplified regions that were positively correlated with proliferation and showed an increased amplification frequency (q < 0.05). We next examined the RNAi data in all breast cancer cell lines ( Supplementary  Fig. 6a ) and in luminal HER2 + cell lines (Supplementary Fig. 6b ) in the context of the PAM50 proliferation signature (Supplementary Table 61 ). Comparing the results of these four analyses (Fig. 5a) identified 19 genes that were uniquely essential for cell viability in luminal cell lines and that were amplified in highly proliferative luminal tumors (Fig. 5b) . Two additional genes, DNAJC5 and SNX21, were identified by RNAi analysis but were initially overlooked in the CNA analyses, as they were located at the cusp of two segmented regions; however, because genes overlapping both 5′ and 3′ of these genes were amplified, we included them in further investigations. Of these 21 candidate genes, 12 showed a significant relationship (P < 0.05) between DNA copy number levels and mRNA expression in luminal tumors (Supplementary Fig. 7) . Notably, half of these genes were located at 20q11-13 (EIF2S2, EIF6, SLC2A10, SNX21, ZBTB46 and DNAJC5), with two located at 3p25.1 (FGD5 and METTL6) and the remaining genes located at 5p15 (TRIO), 11q13 (CPT1A), 12q13 (DTX3) and 17q22-23 (MRPS23). In contrast, permuting the data labels 1,000 times for each analysis, in all samples and in luminal samples alone, identified no gene that met this statistical threshold, suggesting that the 21 candidate genes could not have been identified by chance alone.
Validation of identified candidate genes
We next confirmed that the majority of the identified genes were significantly amplified in highly proliferative luminal breast tumors by analyzing an independent breast tumor data set (Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), n = 1,992) for which both mRNA expression and genomic DNA CNA data were available 3 . Of the 12 genes identified, 9 (FGD5, METTL6, TRIO, CPT1A, DTX3, MRPS23, EIFS2S, EIF6 and SLC2A10) were present on both platforms used in the METABRIC study. Each of these genes (Supplementary Fig. 8 ) showed a significant (P < 0.05) relationship between CNA status and mRNA expression in luminal breast tumors (n = 1,333). Notably, eight of the nine genes, the exception being TRIO, also showed an increased amplification frequency (P < 0.05) in highly proliferative (top quartile) luminal tumors ( Supplementary  Fig. 9 ), thus recapitulating one of our main findings.
To confirm that DNA mutations of genes associated with proliferation in luminal tumors did not confound these results, we examined the relationship between the 11-gene proliferation score and the mutation frequency of the 35 previously identified significantly mutated genes in human breast cancers reported by TCGA 2 . Using a Fisher's exact test (Bonferroni corrected), we determined that only TP53 (q = 7.0 × 10 −10 ) and MAP3K1 (q = 5.0 × 10 −3 ) mutations occurred at significantly different frequencies in highly proliferative Figure 5 Identification of essential genes amplified in highly proliferative luminal tumors. (a) Schematic outlining the integrated genomic strategy used to identify essential genes amplified in highly proliferative luminal breast tumors. (b) Identification of 21 genes in amplified loci that are unique to highly proliferative luminal tumors and are required specifically for luminal cell line proliferation in vitro. mRNA expression of the genes in red and blue was significantly associated with CNA status, with the subset highlighted in red being further validated in the METABRIC data set; genes in black did not show a significant mRNA-DNA correlation. Candidate genes demarcated by asterisks are located at the cusp of a CNA segment and were originally excluded but are mentioned here. Genes marked with # were not included on the mRNA expression microarrays, and the correlation between DNA and mRNA expression was not assessed. 
b npg a n a ly s i s (top quartile) luminal tumors compared to all other samples; TP53 mutations occurred more frequently (51.6% compared to 18.6%) and MAP3K1 (2.1% compared to 12.4%) mutations occurred less frequently in highly proliferative luminal tumors ( Supplementary  Table 62 ). Moreover, we found no significant relationship between MAP3K1 or TP53 mutation status (Bonferroni-corrected Fisher's exact test, q > 0.05) and the amplification status of each candidate gene (Supplementary Table 63) in highly proliferative luminal tumors.
We then investigated whether expression of the candidate genes, independent of CNA status, was associated with proliferation in luminal breast tumors. By comparing the mRNA expression patterns of each candidate gene in highly proliferative luminal tumor samples (top quartile) against all other samples, we found that tumors lacking CNAs of each candidate gene fell into three categories: those that exhibited a positive relationship between mRNA expression and the PAM50 proliferation signature (EIF2S2, EIF6, CPT1A and MRPS23), those that were anticorrelated with the signature (DTX3) and those that showed no correlation (FGD5, METTL6 and SLC2A10) between data sets (Supplementary Fig. 10 ). These data suggest that amplification is a key mechanism driving the expression of these genes. However, our data also suggest, not surprisingly, that overall high expression may be the driver for some genes, which can be accomplished by amplification or through other unknown means.
Candidate gene amplification correlates with poor prognosis
Previous studies have shown that highly proliferative luminal tumors have a poor prognosis 38, 39 ; therefore, we investigated what impact amplification of each candidate gene had on overall survival. From the TCGA (n = 388) 2 and METABRIC (n = 1,333) 3 data sets, we extracted the subset of patients with LumA, LumB or HER2E tumors for which survival data were available (Supplementary Tables 64 and 65) .
We first analyzed data from the TCGA project (Fig. 6a-e) , and despite the relatively short follow-up time (median, 1.7 years), we determined that amplification of FGD5 (P < 0.0001; hazard ratio (HR), 8.0), METTL6 (P = 0.0003; HR, 5.9), DTX3 (P = 0.0387; HR, 2.6) and MRPS23 (P = 0.0078; HR, 2.9) predicted a significantly worse outcome in patients with luminal breast cancer, whereas CPT1A amplification had no effect on patient survival (P = 0.3738). Extending these analyses to the METABRIC data set (Figs. 6f-j) , which had a longer median survival time (7.2 years), confirmed that FGD5 (P = 0.0170; HR, 2.0), METTL6 (P = 0.0081; HR, 2.1), DTX3 (P = 0.0098; HR, 1.8) and MRPS23 (P = 0.0020; HR, 1.5) amplification correlated with a poor prognosis, whereas gain of CPT1A had no effect (P = 0.099) on the survival of patients with luminal breast cancer. The remaining three genes showed no consistent effect on prognosis ( Supplementary  Fig. 11 ). Although it is possibly that other genes within these chromosomal loci are also prognostic, these amplified genes were associated with proliferation in vivo, were prognostic in multiple patient cohorts and are essential for cell viability in vitro.
We likewise determined that for most of the identified candidate genes that failed to meet all our predetermined criteria, amplification alone, without a coordinate increase in mRNA expression, was not sufficient to affect prognosis, as only one (TMEM117) of these genes showed a consistently poor prognosis in the TCGA and METABRIC data sets (Supplementary Table 66) . We then investigated whether the 12 initial candidate genes were predictive of poor prognosis when compared with standard prognostic markers, including molecular subtype, tumor stage, node status, ER status, HER2 status, age at diagnosis and the 11-gene proliferation score, when tested using a multivariate analysis (Cox model). We determined that amplification of a single candidate gene did not consistently outperform or improve the prognostic capacity of these clinical and genomic . Samples in the METABRIC data set missing CNA calls were excluded. For each analysis, the P value was determined by log-rank test, and hazard ratios (HR) are reported. npg a n a ly s i s variables (Supplementary Table 67 ). However, these candidate genes were not identified to be prognostic markers, especially given that they correlate with proliferation, but instead were selected as likely drivers of proliferation, a highly important prognostic feature.
DISCUSSION
Numerous studies, including many that have focused on human breast cancer, used large-scale analyses to investigate the genomic landscape of human cancers in order to identify molecular heterogeneity and define new tumor subtypes not previously recognized 2, 3, 6, 11 . The challenge presented by these studies, and by the enormous amount of genomic data available from resources such as the TCGA and METABRIC projects, is how to integrate multiple forms of genomic data to investigate the biology of disease and how to interpret the relevance of identified genomic alterations without relying on inferences of 'known' biology to determine the role that these alterations have in tumorigenesis.
In this study we utilized gene expression signatures of signaling pathways to identify patterns that can distinguish the known subtypes of breast cancer. These signatures were developed largely from controlled manipulations of the relevant pathways in vitro and are thus based on experimental evidence for pathway activation as opposed to extrapolations of pathway activity achieved from analyses of annotated gene lists. Therefore, the use of an experimentally derived pathway signature, as opposed to an analysis of a single genomic alteration, provides a measure of pathway activity irrespective of how the pathway may have been activated. For instance, a given pathway can be active in a subset of tumors as a result of either an activating alteration (i.e., E2F1 or E2F3 amplification) or an independent event that inactivates a negative regulator of the pathway (i.e., RB1 loss and/or mutation), which nevertheless achieves the same end result (i.e., DNA replication and cell proliferation); notably, we identified these four genetic events as being statistically associated with the RB-LOH signature 16 , which is dominated by E2F-regulated genes and is a strong indicator of cell proliferation and prognosis.
Proliferation is one of the most powerful prognostic features in breast cancers, especially for ER + cancers 38, 39 . Because proliferation is so important, we used a gene expression signature of proliferation as a means to integrate the DNA copy number data, along with data from a genome-wide RNAi screen of luminal breast cancer cell lines, to identify luminal-specific genetic drivers of proliferation. We identified 12 genes that were amplified uniquely in highly proliferative luminal tumors in the TCGA data set, have a correlation between mRNA expression and DNA copy number and have been shown to be essential for luminal breast cancer cell line viability; we validated 8 of these genes using the independent METABRIC data set. Whereas FGD5, METTL6, DTX3 and MRPS23 amplification was prognostic in luminal tumors, these and many of the other identified genes have been reported previously to regulate tumorigenic characteristics, albeit not necessarily in human breast cancer. For example, FGD5 has been shown to regulate the proangiogenic function of VEGF 43 , potentially leading to increased proliferation. DTX3 purportedly promotes Notch signaling 44, 45 , whereas EIF6 is a Notch-dependent regulator of cell invasion and migration 46 , and its inhibition restricts lymphomagenesis and tumor progression 47 . MRPS23 expression is associated with proliferation, oxidative phosphorylation, invasiveness and tumor size in uterine cervical cancer 48 . METTL6 has been reported to contribute to cytotoxic chemotherapy sensitivity in lung cancers 49 .
Several previous studies have identified chromosomal regions altered specifically in subsets of breast cancer, including 3p25 (encompassing METTL6 and FGD5) 2 and 11q13 (CPT1A) 3 in luminal breast tumors; however, these studies neither discriminated between essential and nonessential genes within a specific amplicon nor identified the functional consequences of these alterations. In contrast, we have shown that these regions are amplified uniquely in highly proliferative luminal tumors, and we distinguish between amplified genes that are essential for cell proliferation and are thus likely contribute to tumorigenesis and those that are amplified but are not essential. For instance SRC (20q12-13), which is co-amplified with EIF6, is similarly amplified in a significant (q < 0.01) percentage of highly proliferative luminal tumors (Supplementary Tables 43 and  58 ) but was not identified as being essential in highly proliferative luminal breast cancer cell lines in the RNAi screen ( Supplementary  Table 60 ). Notably, in addition to its role in regulating translation 50 and Notch signaling 46 , EIF6 has been reported to link integrin-β4 to the intermediate filament cytoskeleton 51 , potentially leading to downstream activation of SRC signaling. These results may explain some of the paradoxical findings of SRC in that it may contribute to proliferation status but may not be essential, whereas a gene very near it, which is also linked to proliferation, is essential for cell viability in vitro. Clearly, additional experiments are needed to address this issue, but these results highlight the complex nature and importance of this specific amplicon.
A major challenge to translating these findings into the clinic is the identification of genes within amplicons that are therapeutically targetable. One such event may be amplification of 11q13-14 (CPT1A), which was recently reported 3 to be a defining feature of a high-risk ER + subgroup (integrative cluster 2) and correlates with a poor prognosis in esophageal squamous cell carcinoma 52 . We identified CPT1A as the only gene within the amplified 11q13 locus that is required for cell viability within the confines of the proliferation signature and luminal cell lines, suggesting that repression of CPT1A could affect the proliferative phenotype of these tumors. Consistent with this hypothesis, it was recently reported that RNAi-mediated downregulation, or drug-mediated inhibition, of CPT1A inhibited cancer cell line proliferation, migration and metastasis [53] [54] [55] , although not in breast cancer cell lines. In addition, a specific inhibitor of CPT1A (ST-1326) repressed tumor formation and proliferation in an Eµ-Myc mouse model of Burkett's lymphoma 55 .
Collectively these data demonstrate the ability of this crossplatform genomics approach to identify new oncogenes that are essential for cell viability and are amplified in a subset of patients with highly proliferative luminal breast cancer. These data suggest that not only are these identified genes potential drivers of oncogenesis and that an emphasis should be placed on elucidating their role in breast tumorigenesis but also that they, or their associated pathways, may serve as new therapeutic targets in a subset of human breast cancers for which limited therapeutic opportunities currently exist.
URLs. TCGA data portal, https://tcga-data.nci.nih.gov/docs/ publications/brca_2012/; GenePattern, http://www.broadinstitute. org/cancer/software/genepattern/; COLT database, http://dpsc.ccbr. utoronto.ca/cancer/index.html; European Genome-phenome Archive at the European Bioinformatics Institute, https://www.ebi.ac.uk/ega/; Gene Expression Omnibus (GEO) database, http://www.ncbi.nlm. nih.gov/geo/.
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ONLINE METHODS
Gene expression data. Agilent custom 244K whole-genome gene expression microarray data for human breast cancer samples was acquired from the TCGA project 2 data portal. Samples were filtered to include only those 476 samples for which Affymetrix SNP 6.0 data was present. As previously described 2 , (TCGA) data were median centered for each gene. Illumina HT-29 v3 expression data for the METABRIC project (n = 1,992 samples) were acquired from the European Genome-phenome Archive at the European Bioinformatics Institute, and data were median centered for each gene 3 . Expression data for a panel of 51 breast cancer cell lines were acquired from GEO (GSE12777) 41 . Affymetrix U133+2 data were MAS5.0 normalized using the Affymetrix Expression Console (ver1.2.1.20) and log 2 transformed. Expression probes were collapsed using the median gene value with the GenePattern 56 module CollapseProbes.
Affymetrix SNP 6.0 data. DNA copy number values were determined in 490 TCGA primary breast tumors (476 of which had matched mRNA expression data) and 1,992 METABRIC primary breast tumors using Affymetrix 6.0 SNP arrays as described previously 2, 3 . Copy number segmentation and segment calls (i.e., NEUT, AMP, GAIN, HOMD or HETD) were performed using the circular binary segmentation (CBS) algorithm as described previously 2, 3 . Using the hg19 build annotation from the UCSC genome browser, genes were selected if they fell completely within a CBS-identified copy number segment. Genes that were not found completely within a copy number segment across any sample were filtered out. In the METABRIC data set, the copy number call gene matrix was determined from genes that fell completely within a CBS-identified copy number segment. Out of the 12 genes of interest, SNX21, ZBTB46 and DNAJC5 were not found completely within a CBS-identified segment among the METABRIC samples and were excluded from further analyses.
Gene expression signatures.
A panel of 52 previously published gene expression signatures was used to examine patterns of pathway activity and/or microenvironmental states (Supplementary Table 1 ). To implement each signature, the methods detailed in the original studies were followed as closely as possible. Of these 52 signatures, 22 signatures 10, 11, 32 were originally developed using a Bayesian binary regression strategy and are comprised of Affymetrix probe sets with positive and negative regression weights. These signatures were translated to a form that could be applied to non-Affymetrix expression data. For each signature, we excluded those probe sets with a negative correlation coefficient. The remaining probe sets with a positive coefficient were then translated to the gene level, and replicate genes were merged. To apply a given signature to a new data set, the expression data were filtered to contain only those genes that met the previous criteria, and the mean expression value was calculated using all genes within a given signature that were present in more than 80% of samples. The list of genes in each modified signature is shown in Supplementary Table 2, and the scores for the TCGA data set (Supplementary Table 3 ) and cell line data set are also provided (Supplementary Table 59 ).
Statistical analyses of signature scores. To quantify differences in patterns of signature scores across subtypes, ANOVA followed by Tukey's post-test for pairwise comparisons was used (as shown in Fig. 1b) . To investigate the level of concordance between each of the 52 signatures, the pathway scores calculated for each sample in the TCGA data set (Supplementary Table 3) were analyzed. The R values calculated by Pearson correlation are reported in Supplementary Figure 2 and Supplementary Table 5 .
Identification of point mutations as a function of pathway activity. To compare the frequencies of mutations, the 35 genes identified as being significantly mutated in human breast cancer 2 were assessed in the context of the 11-gene PAM50 proliferation signature 31 . A Fisher's exact test (Bonferroni corrected) was used to compare the frequency of mutations in samples with high (top quartile) and low (all other samples) pathway activity in LumA, LumB and HER2E (n = 388) samples. The frequencies of mutations associated with each group for each signature are summarized in Supplementary Tables 60 and 61.
Identification of CNAs as a function of pathway activity. To identify CNAs, two analysis methods were used independently. Spearman rank correlation, both positive and negative, was used to compare gene-level segment scores with predicted pathway activity. To compare the frequencies of amplifications and losses, a Fisher's exact test was used to compare the frequencies of either gene-specific copy number gains and amplifications or deletions (both LOH and deletions) against nonamplified or nondeleted samples. Samples in the top quartile of the calculated pathway activity were compared to those in the bottom three quartiles. For each analysis, the −log 10 Bonferroni-adjusted P values are reported (Supplementary Figs. 3 and 4) . To identify genes that were significant across both methods, a threshold of q < 0.01 (Bonferroni corrected) was set for validation ( Fig. 2) and q < 0.05 for discovery (Fig. 5) . The Bonferroni-corrected P values for the positive and negative Spearman rank correlation for each gene and each signature are reported in Supplementary Tables 6-57. The frequency of copy number gains in the top quartile compared to all other samples, as well as the Bonferroni-corrected P values calculated by Fisher's exact test, are reported for each gene and each signature (Supplementary Tables 6-57 ).
